SCHEMBL2462429

SCHEMBL2462429

C=CCNc1nnc(Cl)c2ccc(C(=O)Nc3cccc(C(F)(F)F)c3)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 1/20 0.47
KCNQ3 O43525 2/20 0.45
KCNQ2 O43526 2/20 0.45
KCNE1 P15382 2/20 0.45
KCNQ1 P51787 2/20 0.45
KCNK3 O14649 1/20 0.45
RXFP1 Q9HBX9 2/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
TSHR P16473 1/20 0.44
KCNQ5 Q9NR82 1/20 0.44
P2RX1 P51575 1/20 0.44
POLB P06746 1/20 0.44
RHOC P08134 1/20 0.44
RHOA P61586 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459929 0.96 MAPT (0.50) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL12333207 0.89 MAPT (0.50) MAPTLMNAKCNK3KMT2AMEN1
SCHEMBL14548734 0.87 MAPT (0.48) MAPTLMNAKCNK3RXFP1KMT2A
SCHEMBL12333206 0.87 MAPT (0.50) MAPTKDM4ELMNAKCNK3KMT2A
SCHEMBL12254174 0.86 KDM4E (0.48) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL14548733 0.85 MAPT (0.48) MAPTLMNAKCNK3RXFP1KMT2A
SCHEMBL2457621 0.85 RXFP1 (0.55) MAPTALDH1A1HPGDLMNAKCNK3
SCHEMBL2459015 0.85 MAPT (0.65) MAPTLMNAKCNQ3KCNQ2KCNE1
SCHEMBL2459047 0.84 MAPT (0.56) MAPTLMNAKCNQ3KCNQ2KCNE1
SCHEMBL12254173 0.82 KDM4E (0.48) MAPTKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237571-A1 PHTHALAZINE DERIVATIVES ARALDI GIAN-LUCA 2011-09-29 US claimed
US-8044041-B2 e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-10-25 US disclosed
US-20110237571-A1 PHTHALAZINE DERIVATIVES ARALDI GIAN-LUCA 2011-09-29 US disclosed
WO-2008061108-A2 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237571-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 MAPT 653/4885KDM4E 761/4885ALDH1A1 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.